332 related articles for article (PubMed ID: 25829524)
1. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
Beatty PA; Laking GR
J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
[No Abstract] [Full Text] [Related]
2. New NICE criteria for drug access.
Fricker J
Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973
[No Abstract] [Full Text] [Related]
3. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
4. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
5. Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity.
Ragupathy R; Jameson M
N Z Med J; 2016 Aug; 129(1440):22-4. PubMed ID: 27538036
[No Abstract] [Full Text] [Related]
6. The $2.6 billion pill--methodologic and policy considerations.
Avorn J
N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
[No Abstract] [Full Text] [Related]
7. Health, Wealth, and the 21st Century Cures Act.
Lo AW; Philipson TJ; von Eschenbach AC
JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
[No Abstract] [Full Text] [Related]
8. The new $1 billion program created by the U.S. Patient Protection and Affordable Care Act to award federal subsidies to qualifying therapeutic discovery projects. Interview by Annalisa VanHook.
Boegh V; Hecimovich GL
Sci Transl Med; 2010 Jun; 2(38):38pc4. PubMed ID: 20608289
[No Abstract] [Full Text] [Related]
9. Patients not patents: Drug research and development as a public enterprise.
Gøtzsche PC
Eur J Clin Invest; 2018 Feb; 48(2):. PubMed ID: 29243246
[No Abstract] [Full Text] [Related]
10. Industry and regulatory performance in 2012: a year in review.
Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
[TBL] [Abstract][Full Text] [Related]
11. Drug development for neglected diseases - the trouble with FDA review vouchers.
Kesselheim AS
N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
[No Abstract] [Full Text] [Related]
12. Cost of new oncology drugs.
Newcomer L
Clin Adv Hematol Oncol; 2010 May; 8(5):313-4. PubMed ID: 20551889
[No Abstract] [Full Text] [Related]
13. Comparison analysis. Critics questioning design of effectiveness studies.
DoBias M
Mod Healthc; 2009 Feb; 39(8):10. PubMed ID: 19274822
[No Abstract] [Full Text] [Related]
14. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
15. Reforms in the Greek pharmaceutical market during the financial crisis.
Vandoros S; Stargardt T
Health Policy; 2013 Jan; 109(1):1-6. PubMed ID: 22959163
[TBL] [Abstract][Full Text] [Related]
16. Poor ratings. Standard & Poor's report highlights dysfunction in its own realm.
McLaughlin N
Mod Healthc; 2011 Aug; 41(33):17. PubMed ID: 21879673
[No Abstract] [Full Text] [Related]
17. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
American Society of Clinical Oncology
J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
[No Abstract] [Full Text] [Related]
18. Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.
Mancini R; McBride A; Kruczynski M
Oncology (Williston Park); 2013 Sep; 27(9):865-6, 871. PubMed ID: 24282981
[No Abstract] [Full Text] [Related]
19. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
20. Rewarding innovation in drug discovery.
Lopes G
Health Aff (Millwood); 2009; 28(3):922-3. PubMed ID: 19414906
[No Abstract] [Full Text] [Related]
[Next] [New Search]
